237 related articles for article (PubMed ID: 25310357)
1. Ezetimibe prevents the development of non‑alcoholic fatty liver disease induced by high‑fat diet in C57BL/6J mice.
Wang X; Ren Q; Wu T; Guo Y; Liang Y; Liu S
Mol Med Rep; 2014 Dec; 10(6):2917-23. PubMed ID: 25310357
[TBL] [Abstract][Full Text] [Related]
2. P2Y2R Deficiency Ameliorates Hepatic Steatosis by Reducing Lipogenesis and Enhancing Fatty Acid β-Oxidation through AMPK and PGC-1α Induction in High-Fat Diet-Fed Mice.
Dusabimana T; Park EJ; Je J; Jeong K; Yun SP; Kim HJ; Kim H; Park SW
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073834
[TBL] [Abstract][Full Text] [Related]
3. Ezetimibe prevents hepatic steatosis induced by a high-fat but not a high-fructose diet.
Ushio M; Nishio Y; Sekine O; Nagai Y; Maeno Y; Ugi S; Yoshizaki T; Morino K; Kume S; Kashiwagi A; Maegawa H
Am J Physiol Endocrinol Metab; 2013 Jul; 305(2):E293-304. PubMed ID: 23715726
[TBL] [Abstract][Full Text] [Related]
4. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
[TBL] [Abstract][Full Text] [Related]
5. The Niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of obese male mice.
Sugizaki T; Watanabe M; Horai Y; Kaneko-Iwasaki N; Arita E; Miyazaki T; Morimoto K; Honda A; Irie J; Itoh H
Endocrinology; 2014 Aug; 155(8):2810-9. PubMed ID: 24773344
[TBL] [Abstract][Full Text] [Related]
6. Ezetimibe increases hepatic iron levels in mice fed a high-fat diet.
Kishino Y; Tanaka Y; Ikeda T; Yamamoto K; Ogawa H; Iwatani Y; Kamisako T
J Pharmacol Exp Ther; 2013 Jun; 345(3):483-91. PubMed ID: 23538201
[TBL] [Abstract][Full Text] [Related]
7. Anti-hepatic steatosis activity of Sicyos angulatus extract in high-fat diet-fed mice and chemical profiling study using UHPLC-qTOF-MS/MS spectrometry.
An JP; Choi JH; Huh J; Lee HJ; Han S; Noh JR; Kim YH; Lee CH; Oh WK
Phytomedicine; 2019 Oct; 63():152999. PubMed ID: 31280138
[TBL] [Abstract][Full Text] [Related]
8. Chronic administration of recombinant IL-6 upregulates lipogenic enzyme expression and aggravates high-fat-diet-induced steatosis in IL-6-deficient mice.
Vida M; Gavito AL; Pavón FJ; Bautista D; Serrano A; Suarez J; Arrabal S; Decara J; Romero-Cuevas M; Rodríguez de Fonseca F; Baixeras E
Dis Model Mech; 2015 Jul; 8(7):721-31. PubMed ID: 26035386
[TBL] [Abstract][Full Text] [Related]
9. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
Zheng S; Hoos L; Cook J; Tetzloff G; Davis H; van Heek M; Hwa JJ
Eur J Pharmacol; 2008 Apr; 584(1):118-24. PubMed ID: 18329014
[TBL] [Abstract][Full Text] [Related]
10. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease.
Liu X; Chen S; Zhang L
Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E34-E42. PubMed ID: 32228319
[TBL] [Abstract][Full Text] [Related]
11. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet.
Muraoka T; Aoki K; Iwasaki T; Shinoda K; Nakamura A; Aburatani H; Mori S; Tokuyama K; Kubota N; Kadowaki T; Terauchi Y
Metabolism; 2011 May; 60(5):617-28. PubMed ID: 20673929
[TBL] [Abstract][Full Text] [Related]
12. Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor.
Dong R; Yang X; Wang C; Liu K; Liu Z; Ma X; Sun H; Huo X; Fu T; Meng Q
Phytomedicine; 2019 Feb; 53():134-142. PubMed ID: 30668392
[TBL] [Abstract][Full Text] [Related]
13. Psoralea corylifolia L. extract ameliorates nonalcoholic fatty liver disease in free-fatty-acid-incubated HEPG2 cells and in high-fat diet-fed mice.
Hong Y; Choi SI; Hong E; Kim GH
J Food Sci; 2020 Jul; 85(7):2216-2226. PubMed ID: 32579753
[TBL] [Abstract][Full Text] [Related]
14. Sesamin ameliorates nonalcoholic hepatic steatosis by inhibiting CD36-mediated hepatocyte lipid accumulation in vitro and in vivo.
Bai YP; Zhang T; Hu ZY; Zhang Y; Wang DG; Zhou MY; Zhang Y; Zhang F; Kong X
Biochem Pharmacol; 2024 Jun; 224():116240. PubMed ID: 38679210
[TBL] [Abstract][Full Text] [Related]
15. Pu-erh tea extract ameliorates high-fat diet-induced nonalcoholic steatohepatitis and insulin resistance by modulating hepatic IL-6/STAT3 signaling in mice.
Cai X; Fang C; Hayashi S; Hao S; Zhao M; Tsutsui H; Nishiguchi S; Sheng J
J Gastroenterol; 2016 Aug; 51(8):819-29. PubMed ID: 26794005
[TBL] [Abstract][Full Text] [Related]
16. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
[TBL] [Abstract][Full Text] [Related]
17. Chokeberry attenuates the expression of genes related to de novo lipogenesis in the hepatocytes of mice with nonalcoholic fatty liver disease.
Park H; Liu Y; Kim HS; Shin JH
Nutr Res; 2016 Jan; 36(1):57-64. PubMed ID: 26773781
[TBL] [Abstract][Full Text] [Related]
18. Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model.
Orime K; Shirakawa J; Togashi Y; Tajima K; Inoue H; Nagashima Y; Terauchi Y
Eur J Pharmacol; 2016 Feb; 772():22-32. PubMed ID: 26724391
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Effect of Gypenosides on Nonalcoholic Steatohepatitis via Regulating Hepatic Lipogenesis and Fatty Acid Oxidation.
Li H; Ying H; Hu A; Hu Y; Li D
Biol Pharm Bull; 2017; 40(5):650-657. PubMed ID: 28458350
[TBL] [Abstract][Full Text] [Related]
20. Pathophysiological importance of bile cholesterol reabsorption: hepatic NPC1L1-exacerbated steatosis and decreasing VLDL-TG secretion in mice fed a high-fat diet.
Toyoda Y; Takada T; Yamanashi Y; Suzuki H
Lipids Health Dis; 2019 Dec; 18(1):234. PubMed ID: 31883528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
